CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-491

Not that hard to understand and full year out soon. Even if you thought this was 10-20% overvalued it's not much in the context of things and with increased revenue cashflow positivity might be on the cusp with the current cap raise.

if market goes down this could go down 50% as a spec cashflow negative microcap.

plenty of medical device companies trading for a lot more with 0 sales, versus this company that has brought multiple revenue generating products onto the market, selling a division for $100m

So if you can propose a different company in the healthcare sector that trades on 2 times sales with better cashflow and revenue id be interested to know as id probably invest if sales would increase.

Financials aren't up to date as annual report is due out in a couple of weeks. That is just standard reporting practices of any asx listed companies only quarterlies for new spec stocks, this would have needed to produce 4cs if it weren't for Ellex days but it is what it is